5月5日 - ** 医疗设备制造商Revvity RVTY.N的股价在盘前交易中上涨2.7%，至88.8美元
** Revvity公布第一季度经调整每股收益为1.06美元（(link)），高于LSEG汇总的分析师平均预期1.02美元
** 该公司将2026年调整后每股收益预期下调至5.20至5.30美元区间，此前预期为5.35至5.45美元
** 分析师此前预期年度每股收益为5.39美元
** 公司表示已决定出售其中国免疫诊断业务，该业务在2025财年约占总收入的6%
** 截至上一交易日收盘，该公司股价年内累计下跌10.6%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.